TGTX
What one share of Tg Therapeutics holds
Pharmaceutical Preparations
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
Tg Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.01 |
|---|---|
| Profit | $2.77 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.11 |
| Cash and investments | $3.15 |
| Debt | $4.87 |
| Book value | $3.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$1.60 | $0.01 | −$1.26 | — | $0.63 |
| 2017 | $0.00 | −$1.91 | $0.00 | −$1.51 | — | $0.92 |
| 2018 | $0.00 | −$2.30 | $0.00 | −$1.71 | — | $0.29 |
| 2019 | $0.00 | −$1.96 | $0.00 | −$1.50 | — | $0.35 |
| 2020 | $0.00 | −$2.42 | $0.00 | −$1.86 | — | $3.69 |
| 2021 | $0.05 | −$2.63 | $0.00 | −$2.24 | — | $1.66 |
| 2022 | $0.02 | −$1.65 | $0.00 | −$1.30 | — | $0.40 |
| 2023 | $1.57 | $0.09 | $0.00 | −$0.21 | — | $1.06 |
| 2024 | $2.05 | $0.15 | $0.00 | −$0.25 | — | $1.43 |
| 2025 | $3.82 | $2.77 | $0.00 | −$0.15 | — | $4.17 |